These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32930107)

  • 1. Tanapoxvirus: From discovery towards oncolytic immunovirotherapy.
    Suryawanshi YR; Zhang T; Razi F; Essani K
    J Cancer Res Ther; 2020; 16(4):708-712. PubMed ID: 32930107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells.
    Zhang T; Kordish DH; Suryawanshi YR; Eversole RR; Kohler S; Mackenzie CD; Essani K
    Curr Cancer Drug Targets; 2018; 18(6):577-591. PubMed ID: 28669340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors.
    Monaco ML; Idris OA; Filpi GA; Kohler SL; Haller SD; Burr JE; Eversole R; Essani K
    Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
    Breitbach CJ; Thorne SH; Bell JC; Kirn DH
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.
    Suryawanashi YR; Zhang T; Woyczesczyk HM; Christie J; Byers E; Kohler S; Eversole R; Mackenzie C; Essani K
    Med Oncol; 2017 Jun; 34(6):112. PubMed ID: 28466296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release.
    Zhang T; Essani K
    Virus Genes; 2017 Jun; 53(3):477-482. PubMed ID: 28188458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.
    Zhang T; Suryawanshi YR; Kordish DH; Woyczesczyk HM; Jeng D; Essani K
    Virus Genes; 2017 Feb; 53(1):52-62. PubMed ID: 27738905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.
    Conrad SJ; El-Aswad M; Kurban E; Jeng D; Tripp BC; Nutting C; Eversole R; Mackenzie C; Essani K
    J Exp Clin Cancer Res; 2015 Feb; 34(1):19. PubMed ID: 25887490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viruses as nanomedicine for cancer.
    Badrinath N; Heo J; Yoo SY
    Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies.
    Gujar S; Pol JG; Kim Y; Lee PW; Kroemer G
    Trends Immunol; 2018 Mar; 39(3):209-221. PubMed ID: 29275092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United virus: the oncolytic tag-team against cancer!
    Le Boeuf F; Bell JC
    Cytokine Growth Factor Rev; 2010; 21(2-3):205-11. PubMed ID: 20227326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting autophagy to enhance oncolytic virus-based cancer therapy.
    Meng S; Xu J; Wu Y; Ding C
    Expert Opin Biol Ther; 2013 Jun; 13(6):863-73. PubMed ID: 23488666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poxvirus oncolytic virotherapy.
    Torres-Domínguez LE; McFadden G
    Expert Opin Biol Ther; 2019 Jun; 19(6):561-573. PubMed ID: 30919708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer.
    Stanford MM; McFadden G
    Expert Opin Biol Ther; 2007 Sep; 7(9):1415-25. PubMed ID: 17727330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction between oncolytic viruses augments tumor killing.
    Le Boeuf F; Diallo JS; McCart JA; Thorne S; Falls T; Stanford M; Kanji F; Auer R; Brown CW; Lichty BD; Parato K; Atkins H; Kirn D; Bell JC
    Mol Ther; 2010 May; 18(5):888-95. PubMed ID: 20234341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.
    Breitbach CJ; Reid T; Burke J; Bell JC; Kirn DH
    Cytokine Growth Factor Rev; 2010; 21(2-3):85-9. PubMed ID: 20472490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.